Brief: Cytodyn Says 1st 2 Patients Enrolled In Randomized Phase 2, Covid-19 Trial With Leronlimab
06/04/2020 11:10
April 6 (Reuters) - Cytodyn Inc CYDY.PK :
* FIRST TWO PATIENTS ENROLLED IN RANDOMIZED PHASE 2,
COVID-19
TRIAL WITH LERONLIMAB; FIVE MORE SEVERELY ILL COVID-19 PATIENTS
TREATED UNDER EMERGENCY IND AND TWO PATIENTS HAVE ALREADY
EXTUBATED
* CYTODYN- PATIENTS ENROLLED IN COVID-19 TRIAL EXPECTED TO
BE
ADMINISTERED LERONLIMAB FOR 2 WEEKS, WITH PRIMARY ENDPOINT BEING
MORTALITY RATE AT 14 DAYS
Source text for Eikon: ID:nGNX7Ql2TG
Further company coverage: CYDY.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer